These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28615167)

  • 1. Drugs with FDA accelerated approval often have weak evidence, study finds.
    Dyer O
    BMJ; 2017 Jun; 357():j2905. PubMed ID: 28615167
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 5. How FDA approves biotechnology drugs.
    Manuel SM; Piascik P
    Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA evaluates accelerated approval process. Food and Drug Administration.
    Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA approval signals more 'homework' on the horizon in trials.
    Waters H
    Nat Med; 2011 Jul; 17(7):754. PubMed ID: 21738130
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA draft guidance and health-outcomes research.
    Revicki DA;
    Lancet; 2007 Feb; 369(9561):540-2. PubMed ID: 17307086
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA under pressure to relax drug rules.
    Ledford H
    Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
    [No Abstract]   [Full Text] [Related]  

  • 11. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 12. US Food and Drug Administration and design of drug approval studies.
    Woloshin S; Schwartz LM; Frankel B; Faerber A
    JAMA; 2014 Nov; 312(20):2163-5. PubMed ID: 25423223
    [No Abstract]   [Full Text] [Related]  

  • 13. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. News from the Society for Women's Health Research: FDA doing poor job of monitoring drugs for sex differences.
    Greenberger P
    J Womens Health Gend Based Med; 2001 Nov; 10(9):829-30. PubMed ID: 11747675
    [No Abstract]   [Full Text] [Related]  

  • 15. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 16. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 17. Early accelerated approval for highly targeted cancer drugs.
    Chabner BA
    N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
    Peck CC; Rubin DB; Sheiner LB
    Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 20. Errors in 'Trials and error'.
    Miller DD
    Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.